At least 39 drugs developed and marketed by biotech companies are anticipated to have more than $500 million in sales in 2012. This compares to at least 35 in 2011. While Adderall XR dextroamphetamine/amphetamin from Shire plc (LSE:SHP; NASDAQ:SHPG) is no longer expected to post sales above $500 million, five new drugs have entered the list this year: Angiomax bivalirudin from The Medicines Co. (NASDAQ:MDCO); Cimzia ertolizumab pegol from UCB Group (Euronext:UCB); Eylea aflibercept from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN); Prolia/Xgeva denosumab from Amgen Inc. (NASDAQ:AMGN); and Replagal agalsidase alfa from Shire plc (LSE:SHP; NASDAQ:SHPG).

Product sales as reported by companies listed below, unless otherwise noted. Included are drugs developed by biotechs that were acquired - Amylin Pharmaceuticals LLC; Cephalon Inc.; Genentech Inc.; Genzyme Corp.; MedImmune LLC; and OSI Pharmaceuticals LLC - but